2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
85
Recurrence
10
Lymphoma
8
Leukemia, Myeloid, Acute
6
Immunoglobulin Light-chain Amyloidosis
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Mantle-Cell
5
Waldenstrom Macroglobulinemia
4
Neoplasms, Plasma Cell
3
Hematologic Neoplasms
3
Plasmacytoma
2
Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Leukemia, Plasma Cell
2
Leukemia, Biphenotypic, Acute
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Amyloidosis
2
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Proteostasis Deficiencies
1
Plasmablastic Lymphoma
1
POEMS Syndrome
1
Neurofibrosarcoma
1
Interventions
Melphalan
3
Blood Specimen Collection
3
Magnetic Resonance Spectroscopy
2
thymoglobulin
1
sargramostim
1
romidepsin
1
montanide ISA 51
1
keyhole-limpet hemocyanin
1
ixazomib
1
detox adjuvant
1
Waiting Lists
1
Ursodeoxycholic Acid
1
Transplantation
1
Thalidomide
1
Tablets
1
Surveys and Questionnaires
1
Streptozocin
1
Specimen Handling
1
Restraint, Physical
1
Radiosurgery
1
Radiation
1
Mercaptopurine
1
Leucovorin
1
Ketoconazole
1
Interleukin-2
1
Fulvestrant
1
Floxuridine
1
FANG vaccine
1
Docetaxel
1
Diagnostic Tests, Routine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genetic Diseases, Inborn
×
ixazomib
×
Clear all
NCT03683277
2025-02-19
IFM2014-01
Intergroupe Francophone du Myelome
Phase 2
Terminated
26 enrolled